These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 29508475)

  • 1. Effect of aripiprazole monotherapy in a patient presenting with delayed sleep phase syndrome associated with depressive symptoms.
    Suzuki H; Hibino H; Inoue Y; Mikami K
    Psychiatry Clin Neurosci; 2018 May; 72(5):375-376. PubMed ID: 29508475
    [No Abstract]   [Full Text] [Related]  

  • 2. Improvement of a patient's circadian rhythm sleep disorders by aripiprazole was associated with stabilization of his bipolar illness.
    Tashiro T
    J Sleep Res; 2017 Apr; 26(2):247-250. PubMed ID: 28116759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aripiprazole monotherapy can relieve ruminations in a case with nonpsychotic depression.
    Hou YC; Lai CH
    J Neuropsychiatry Clin Neurosci; 2014; 26(4):E32-3. PubMed ID: 26037881
    [No Abstract]   [Full Text] [Related]  

  • 4. Aripiprazole is effective for treatment of delayed sleep phase syndrome.
    Takaki M; Ujike H
    Clin Neuropharmacol; 2014; 37(4):123-4. PubMed ID: 24992089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response and remission rates with adjunctive aripiprazole in patients with major depressive disorder who exhibit minimal or no improvement on antidepressant monotherapy.
    Casey DE; Laubmeier KK; Eudicone JM; Marcus R; Berman RM; Rahman Z; Sheehan J
    Int J Clin Pract; 2014 Nov; 68(11):1301-8. PubMed ID: 25196314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining moderators to identify clinical profiles of patients who will, and will not, benefit from aripiprazole augmentation for treatment resistant late-life major depressive disorder.
    Smagula SF; Wallace ML; Anderson SJ; Karp JF; Lenze EJ; Mulsant BH; Butters MA; Blumberger DM; Diniz BS; Lotrich FE; Dew MA; Reynolds CF
    J Psychiatr Res; 2016 Oct; 81():112-8. PubMed ID: 27438687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moderators of Remission in Patients With Late-Life Depression: Where Do We Go Next?
    Taylor WD
    JAMA Psychiatry; 2016 Apr; 73(4):319-20. PubMed ID: 26963364
    [No Abstract]   [Full Text] [Related]  

  • 8. Predictors and Moderators of Remission With Aripiprazole Augmentation in Treatment-Resistant Late-Life Depression: An Analysis of the IRL-GRey Randomized Clinical Trial.
    Kaneriya SH; Robbins-Welty GA; Smagula SF; Karp JF; Butters MA; Lenze EJ; Mulsant BH; Blumberger D; Anderson SJ; Dew MA; Lotrich F; Aizenstein HJ; Diniz BS; Reynolds CF
    JAMA Psychiatry; 2016 Apr; 73(4):329-36. PubMed ID: 26963689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out.
    Citrome L
    Int J Clin Pract; 2015 Nov; 69(11):1211-20. PubMed ID: 26477545
    [No Abstract]   [Full Text] [Related]  

  • 10. Central sleep apnea in a geriatric patient treated with aripiprazole.
    Kohen I; Sarcevic A
    Am J Ther; 2009; 16(2):197-8. PubMed ID: 19300045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of ramelteon on a patient with circadian rhythm sleep disorder and mood disorder].
    Yoshihara S; Yoshizawa M; Shirata A; Matsuda M; Tamashiro M; Saito I; Sakamoto K; Fujimura Y; Tamura Y; Chiba S
    Seishin Shinkeigaku Zasshi; 2014; 116(9):746-51. PubMed ID: 25711117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aripiprazole-related subcortical growth in a patient with major depressive disorder and panic disorder.
    Lai CH
    J Clin Psychopharmacol; 2010 Aug; 30(4):474-6. PubMed ID: 20631573
    [No Abstract]   [Full Text] [Related]  

  • 13. Aripiprazole monotherapy in a patient with major depressive disorder.
    Yokoyama Y; Kitamura H; Someya T
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):1124-5. PubMed ID: 20398715
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of Prior Treatment on Remission of Late-Life Depression with Venlafaxine and Subsequent Aripiprazole or Placebo Augmentation.
    Hsu JH; Mulsant BH; Lenze EJ; Karp JF; Lavretsky H; Roose SP; Reynolds CF; Blumberger DM
    Am J Geriatr Psychiatry; 2016 Oct; 24(10):918-22. PubMed ID: 27538352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global benefit-risk analysis of adjunctive aripiprazole in the treatment of patients with major depressive disorder.
    Wisniewski SR; Chen CC; Kim E; Kan HJ; Guo Z; Carlson BX; Tran QV; Pikalov A
    Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):965-72. PubMed ID: 19662630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
    Trivedi MH; Thase ME; Fava M; Nelson CJ; Yang H; Qi Y; Tran QV; Pikalov A; Carlson BX; Marcus RN; Berman RM
    J Clin Psychiatry; 2008 Dec; 69(12):1928-36. PubMed ID: 19192475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential utility of aripiprazole monotherapy for the treatment of major depressive disorder comorbid with obsessive-compulsive disorder.
    Pae CU
    Psychiatry Clin Neurosci; 2009 Aug; 63(4):593. PubMed ID: 19659566
    [No Abstract]   [Full Text] [Related]  

  • 18. Normalization of prolactin with aripiprazole in a patient with psychotic depression and a comorbid pituitary microadenoma.
    Steinhagen CK
    Psychosomatics; 2007; 48(4):350-1. PubMed ID: 17600173
    [No Abstract]   [Full Text] [Related]  

  • 19. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies.
    Thase ME; Jonas A; Khan A; Bowden CL; Wu X; McQuade RD; Carson WH; Marcus RN; Owen R
    J Clin Psychopharmacol; 2008 Feb; 28(1):13-20. PubMed ID: 18204335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of extended release quetiapine fumarate monotherapy in elderly patients with major depressive disorder: secondary analyses in subgroups of patients according to baseline anxiety, sleep disturbance, and pain levels.
    Montgomery SA; Altamura AC; Katila H; Datto C; Szamosi J; Eriksson H
    Int Clin Psychopharmacol; 2014 Mar; 29(2):93-105. PubMed ID: 24162081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.